The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03401827

Recruitment Status : Unknown

Verified January 2018 by Sang Hyub Lee, Seoul National University Hospital.
Recruitment status was: Recruiting

First Posted : January 17, 2018

Last Update Posted : February 12, 2018

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Sang Hyub Lee, Seoul National University Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	January 1, 2019
Estimated Study Completion Date :	January 1, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Huh G, Lee HS, Choi JH, Lee SH, Paik WH, Ryu JK, Kim YT, Bang S, Lee ES. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. Ther Adv Med Oncol. 2021 Nov 10;13:17588359211056179. doi: 10.1177/17588359211056179. eCollection 2021.

To Top